Services
Research and Clinical Development
Regulatory
Clinical
Biometrics
CMC
Consulting
Management Consulting
Market Access
Patient Engagement
Transaction Advisory
Lifecycle Optimization
Lifecycle Optimization
Real-World Solutions
Real-World Solutions
Biotech
Biotech
Technology
Health Storylines
A digital platform that puts patients at the center and intersection of human networks, technology, and science
b.research
A single, unified SaaS solution for all EU Phase 4, Real-World Evidence, and Post-Approval studies
RedCrow
An equity crowdfunding and crowdsourcing platform for healthcare innovation
About
Our team
Our team collaborates to fully understand every aspect of each client’s organization from concept ideation to commercial realization, from innovation to implementation
Community involvement
We work with our local and global communities to create positive change through education, service, and sustainable business practices
800+
employees
90+%
has a PhD and/or Masters
15
languages spoken
30
nationalities
Careers
Job openings
Explore our job openings and find the one that is right for you
Why work at Alira Health?
Alira Health is dedicated to providing market-leading professional development, education, travel, and work-life benefits to all team members
Join our team
Join our global team dedicated to innovation and initiative, where physical walls and different time zones don’t limit, but encourage, collaboration
Resources
News
Read all the latest from us
Blog
Insights on healthcare innovation and more
Events
Check out our upcoming events
Publications
Discover our latest industry infographics, articles, white papers, and more
Multimedia
Visit our videos, podcasts, webinars, and more.
Latest in the hub
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Published: September, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
Published: September, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Published: September, 2023
Services
Overview
Research and Clinical Development
Regulatory Clinical Biometrics CMC
Consulting
Management Consulting Market Access Patient Engagement Transaction Advisory Lifecycle Optimization
Real-World Solutions
Real-World Solutions
Biotech
Biotech
Technology
Overview Health Storylines b.research RedCrow
About
Overview Our team Community involvement
Careers
Overview Job openings Why work at Alira Health? Join our team
Resources
Overview News Blog Events Publications Multimedia
Home > Education Hub > EADV Congress 2022

EADV Congress 2022

September 7-10, 2022 | Milan & Online

We are pleased to share that our team will be attending EADV Congress 2022 in Milan this September. EADV Congress is an outstanding educational and learning experience for dermatologists and venereologists world-wide, and our team will be pleased to join it alongside our partner Legit.Health.

Alira Health and Legit.Health will be attending EADV Congress 2022 following the roll-out of the unique next generation technology solution for dermatology DCT, RWE and DTx. This joint solution is designed to automate the verification of inclusion criteria, automate participant monitoring and clinical endpoint acquisition and recruitment, and increase the diversity of participants. Learn more about the solution from the partnership announcement.

Events
Category:
Decentralized Clinical Trials Digital Therapeutics Real-World Evidence (RWE)
Published on:
September 6, 2022
Our delegates
Andrea Mantovani

Andrea Mantovani

 Vice President, Global Market Access & Pricing, Alira Health
Kumara Prasad Palanivel

Dr. Kumara Prasad Palanivel

 Director, Digital Medical Strategy, Alira Health

Would you like to meet at EADV and learn more about our unique platform for dermatology DCT, RWE and DTx?

Contact us to set up a meeting

Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Events June 13, 2023
DSVR 2023
We are excited to share that we will be attending the DSVR 2023 - 15° Colloque Données de Santé en Vie Réelle.
France Real-World Evidence (RWE)
Blog May 4, 2023
How to Leverage Real-World Evidence to Achieve Orphan Drug Designation
Obtaining an orphan drug designation (ODD) is challenging and may require sponsors to leverage real-world evidence (RWE). Read the article to learn what ODD is, why it matters, and how RWE can help.
Orphan Drug Rare Disease Real-World Evidence (RWE)
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
See all news
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.